Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01448525 · ClinicalTrials.gov registry record · Phase 4
Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence
A Phase 4 study of Hypotrichosis, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 88
- Enrollment target
- 1
- Study location
NCT01448525: Completed Phase 4 study of Hypotrichosis, sponsored by Allergan.
NCT01448525 is a Phase 4 study of Hypotrichosis that has completed, run by Allergan. The registered enrollment target is 88 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01448525, a Phase 4 study of Hypotrichosis, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 88 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine patient satisfaction with LATISSE® treatment for increasing eyelash prominence.
Primary Outcome
Participants rated their overall eyelash satisfaction by answering Eyelash Satisfaction Questionnaire (ESQ-9) question #3: "Overall, how satisfied are you with your eyelashes?" using a 5-point scale: -2=very unsatisfied (worst), -1=unsatisfied, 0=neutral, 1=satisfied or 2=very satisfied (best). The percentage of participants who rated their satisfaction as 1=satisfied or 2=very satisfied at Week 16 is reported.
Conditions Studied
Interventions
- DRUG bimatoprost ophthalmic solution 0.03%
- DRUG bimatoprost vehicle solution
Study Locations (1)
Florida
- - Coral Gables
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2011-10 |
| Est. Completion | 2012-04 |
| Phase | Phase 4 |
What the finished NCT01448525 record still lists
NCT01448525 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Hypotrichosis appearing as the primary indexed condition, and to 2 interventions - of which bimatoprost ophthalmic solution 0.03% is the first listed.
NCT01448525 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT01448525 about?
NCT01448525 is a clinical study titled "Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence". The purpose of this study is to determine patient satisfaction with LATISSE® treatment for increasing eyelash prominence.
What is the current status of trial NCT01448525?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 88 participants. The study started on 2011-10. Estimated completion is 2012-04.
What conditions does trial NCT01448525 study?
This clinical trial studies the following conditions: Hypotrichosis.
What interventions are being tested in trial NCT01448525?
The interventions under investigation include: bimatoprost ophthalmic solution 0.03% (DRUG), bimatoprost vehicle solution (DRUG).
Who is sponsoring clinical trial NCT01448525?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01448525 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypotrichosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01448525's enrollment target sits among peer trials
88 916th of 2000 higher than 1,079 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia